COMP <GO>
SNDX vs SLN // NET PROFIT MARGIN
Syndax Pharmaceuticals Inc. (NASDAQ) VS. Silence Therapeutics Plc American Depository Share (NASDAQ) • 15-METRIC TALLY: SNDX 2
— SLN 2
■ METRIC PARITY
LAST: $14.15 (-1.19%) • MKT CAP: $1.26B
net-margins
-60.00%
LAST: $19.80 (+0.46%) • MKT CAP: $1.23B
net-margins
-60.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SNDX VS. SLN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SNDX | SLN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 61.50% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -5.06% | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | -60.00% | 0.00 | TIE | /operating-margins <GO> |
| Net Profit Margin ACTIVE | -60.00% | -60.00% | 0.00 | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | -65.00% | +245.00 | SNDX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 3.36 | -3.16 | SLN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 3/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 41.2 | 79.0 | -37.80 | SLN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.26B | $1.23B | $32.9M | SNDX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SNDX REV | SLN REV | SNDX GROSS % | SLN GROSS % | SNDX FCF | SLN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $172.4M | $559.0K | — | 61.5% | -$323.2M | -$62.3M |
| FY 2024 | $23.7M | $43.3M | — | 72.7% | -$274.9M | -$67.9M |
| FY 2023 | $0 | $31.6M | — | — | -$160.6M | -$49.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SNDX // BETA —
SLN // BETA —